CoChat

Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors

Open access
Gandini, Annachiara, Bartolini, Manuela, Tedesco, Daniele, Martinez-Gonzalez, Loreto, Roca, Carlos, Campillo, Nuria E., Zaldivar-Diez, Josefa, Perez, Concepción, Zuccheri, Giampaolo, Miti, Andrea, Feoli, Alessandra, Castellano, Sabrina, Petralla, Sabrina, Monti, Barbara, Rossi, Martina, Moda, Fabio, Legname, Giuseppe, Martinez, Ana, Bolognesi, Maria Laura · 2018 · Journal of Medicinal Chemistry
Cited by 107

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Several findings propose the altered tau protein network as an important target for Alzheimer’s disease (AD). Particularly, two points of pharmacological intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3β and tau aggregation process. On the basis of this consideration and on our interest in multitarget paradigms in AD, we report on the discovery of 2,4-thiazolidinedione derivatives endowed with such a profile. 28 and 30 displayed micromolar IC50 values toward GSK-3β, together with the capacity of inhibiting AcPHF6 aggregation of 60% and 80% at 10 μM, respectively. In addition, they showed PAMPA-BBB permeability, together with a suitable cellular safety profile. 30 also displayed inhibition of both K18 and full-length tau aggregations. Finally, both compounds were able to improve cell viability in an okadaic acid-induced neurodegeneration cell model. To the best of our knowledge, 28 and 30 are the first balanced, nontoxic, dual-acting compounds hitting tau cascade at two different hubs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.8b00610

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 107

Metadata

Authors
Gandini, A., Bartolini, M., Tedesco, D., Martinez-Gonzalez, L., Roca, C., Campillo, N. E., Zaldivar-Diez, J., Perez, C., Zuccheri, G., Miti, A., Feoli, A., Castellano, S., Petralla, S., Monti, B., Rossi, M., Moda, F., Legname, G., Martinez, A., & Bolognesi, M. L.
Venue
Journal of Medicinal Chemistry
Published
2018-08-04
Volume
61
Issue
17
Pages
7640-7656
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2887806978
Cited by
107
References
15
FWCI
7.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors. https://app.cochat.ai/papers/10.1021/acs.jmedchem.8b00610
The paper
Gandini, A., Bartolini, M., Tedesco, D., Martinez-Gonzalez, L., Roca, C., Campillo, N. E., Zaldivar-Diez, J., Perez, C., Zuccheri, G., Miti, A., Feoli, A., Castellano, S., Petralla, S., Monti, B., Rossi, M., Moda, F., Legname, G., Martinez, A., & Bolognesi, M. L. (2018). Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.8b00610

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.